BU Medical Center press release by Boston University Medical Center, Office of Media Relations
Boston University
OpenBU http://open.bu.edu
BU Publications BU Medical Center: Press Releases
1990-01-10
Boston University Medical Center:
January 10, 1990
https://hdl.handle.net/2144/26357
Boston University
B O S T O N U N I V E R S I T Y S C H O O L OF M E D I C I N E / S C H O O L OF P U B L I C H E A L T H . T H E U N I V E R S I T Y HOSPITAL . B O S T O N U N I V E R S I T Y G O L D M A N S C H O O L OF G R A D U A T E D E N T I S T R Y 
Office of 
Media Relations 
720 Harrison Avenue, Suite 909 
Boston Massachusetts 
02118-2393 
617 638-8491 
Innovations i n the diagnosis and treatment of prostate cancer w i l l be the 
subject of a half-day symposium sponsored j o i n t l y by Boston University School 
of Medicine and the University Hospital's Cancer Care Program. Members of the 
media are i n v i t e d to attend on Saturday, January 15, from 12:50 p.m. to 5 p.m. 
at The Ritz-Carlton Hotel. 
During the conference, experts w i l l present information on advances i n the 
diagnosis of prostate cancer and new hormonal therapies, chemotherapies, and 
surgical techniques. Following the presentations, participants w i l l discuss 
the controversies surrounding these innovations. 
Boston University 
Medical Center 
January 10, 1990 
Dear Member of the Media: 
Prostate cancer i s the number one cancer i n men over 50 and the t h i r d 
leading cause of death from cancer i n men. While uncommon i n younger men, the 
incidence i n that population i s r i s i n g steadily each year. A slowly 
progressing disease, i t i s more aggressive when found i n younger men. 
Although the o r i g i n of prostate cancer i s unknown, experts agree that the 
growth of cancer c e l l s i s related to testosterone. Most therapies, therefore, 
are designed to reduce the amount of testosterone i n the body. 
U n t i l recently, prostate cancer was diagnosed primarily through r e c t a l 
examinations. Several new diagnostic techniques include transrectal 
ultrasound and blood tests for serum markers. Transrectal ultrasound can give 
the physician a detailed image of a tumor even i n the e a r l i e s t stages, while 
the blood tests are helpful i n determining the extent of the disease and 
whether i t has spread to other parts of the body. 
When the cancer i s localized, surgery i s often the treatment chosen. 
Conference participants w i l l discuss the advantages and disadvantages of 
radical prostatectomy (removal of the prostate) to cure prostate cancer i n i t s 
early stages and the pros and cons of a new potency-sparing surgery. 
T r a d i t i o n a l l y , men with metastatic prostate cancer have been given 
estrogren to block testosterone production. Though effec t i v e i n managing 
tumor growth, estrogen increases the r i s k of cardiovascular disease i n men. 
Researchers at the conference w i l l discuss a variety of drugs that show a 
si g n i f i c a n t e f f e c t on cancer growth without the side effects of estrogen. 
Standard chemotherapy has not been successful i n the treatment of prostate 
cancer, but there are some promising new drugs under investigation. The 
conference w i l l h ighlight the results of preliminary research on 
su r a m i n - - i n i t i a l l y developed to tr e a t fungal diseases and AIDS--that 
apparently blocks testosterone and destroys cancer c e l l s . 
I f you are interested i n attending the conference or would l i k e to 
interview any of the experts who w i l l be attending, please c a l l me at 638-8491 
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